<DOC>
	<DOCNO>NCT00045474</DOCNO>
	<brief_summary>RATIONALE : Brachytherapy use radioactive material kill cancer cell remain surgery . PURPOSE : Phase I trial study effectiveness brachytherapy treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Brachytherapy Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose brachytherapy use intracavitary applicator liquid iodine I 125 patient recurrent malignant glioma . - Determine acute chronic toxicity therapy patient . OUTLINE : This dose-escalation , multicenter study . Within 3-21 day surgical resection , patient receive brachytherapy use intracavity balloon application ( GliaSite ) iodine I 125 solution total 5-7 day . Cohorts 5-10 patient receive escalate dos brachytherapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 10 patient experience dose-limiting toxicity . Patients follow 4 week every 2 month 1 year . PROJECTED ACCRUAL : Approximately 20-30 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Anaplastic astrocytoma , anaplastic oligodendroglioma , glioblastoma multiforme Lowgrade astrocytoma progress highgrade astrocytoma allow Unifocal disease Progressive recurrent radiotherapy without chemotherapy Previously treat least 5,000 cGy external beam radiotherapy 3 month ago Candidate maximal surgical resection Any expect residual enhance tumor must within expect brachytherapy treatment volume Resection must expect result new permanent neurologic deficit No tumor cross 1 cm beyond midline preoperative MRI CT scan No grossly radiographically apparent leptomeningeal spread No ventricular invasion outside anticipated radiotherapy treatment volume No mark edema MRI CT scan Patients 2 separate focus contrastenhancing tumor 5 cm apart preoperative MRI CT scan ineligible PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Not specify Renal Creatinine great 1.7 mg/dL BUN great 2 time upper limit normal Cardiovascular No uncontrolled hypertension No unstable angina pectoris No uncontrolled cardiac dysrhythmia Other Mini mental score least 15 No medical illness would preclude study participation No serious infection No malignancy within past 5 year except curatively treat carcinoma situ cervix nonmelanoma skin cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent biologic agent ( e.g. , immunotoxins , immunoconjugates , antiangiogenesis compound , antisense therapy , peptide receptor antagonist , interferon , interleukin , tumorinfiltrating lymphocyte , lymphokineactivated killer cell , gene therapy ) Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) No concurrent polifeprosan 20 carmustine implant ( Gliadel wafer ) Endocrine therapy Concurrent corticosteroid allow improve quality life Radiotherapy See Disease Characteristics No concurrent radiosurgery Surgery See Disease Characteristics See Radiotherapy Other Recovered prior therapy No prior investigational agent No investigational agent 90 day study participation Concurrent cytotoxic treatment allow improve quality life</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>